Selective sensitivity of solid tumors to suramin in primary cultures of tumor cells from patients
- 3 November 1995
- journal article
- research article
- Published by Wiley in International Journal of Cancer
- Vol. 63 (3) , 356-360
- https://doi.org/10.1002/ijc.2910630309
Abstract
The antineoplastic activity of suramin is currently the subject of clinical trials. We therefore used the semi-automated fluoro-metric microculture cytotoxicity assay (FMCA) to evaluate the cytotoxicity of suramin in vitro in primary cultures of cells from patients with hematological or solid tumors. The activity patterns of some standard cytotoxic agents were included for comparison. A total of 159 samples were tested using continuous drug exposure. Suramin showed relatively high activity against solid tumors, with colorectal, adrenal and kidney carcinomas being the most sensitive, whereas hematological malignancies were more resistant. Suramin and standard drugs showed very low cross-resistance. The results indicate that suramin is differentially active against some solid tumors with comparatively little activity against hematological tumors. The study provides an experimental motive for evaluation of suramin therapy in patients with solid tumors and exploration of less toxic suramin analogues.Keywords
This publication has 20 references indexed in Scilit:
- Synergistic antiproliferative activity of suramin and α2A-interferon against human colorectal adenocarcinoma cell lines: In vitro studiesEuropean Journal Of Cancer, 1994
- Suramin in adrenocortical cancer: limited efficacy and serious toxicityClinical Endocrinology, 1994
- Cytotoxic Drug Sensitivity Testing of Tumor Cells from Patients with Ovarian Carcinoma Using the Fluorometric Microculture Cytotoxicity Assay (FMCA)Gynecologic Oncology, 1994
- Detection of tumor‐specific cytotoxic drug activity IN VITRO using the fluorometric microculture cytotoxicity assay and primary cultures of tumor cells from patientsInternational Journal of Cancer, 1994
- The synergistic and antagonistic effects of cytotoxic and biological agents on the in vitro antitumour effects of suraminEuropean Journal Of Cancer, 1994
- Suramin inhibits growth and transforming growth factor-β1 (TGF-β1) binding in osteosarcoma cell linesEuropean Journal Of Cancer, 1994
- Suramin, an Active Drug for Prostate Cancer: Interim Observations in a Phase I TrialJNCI Journal of the National Cancer Institute, 1993
- Suramin in advanced platinum-resistant ovarian cancerEuropean Journal Of Cancer, 1992
- Effects of Suramin on In Vitro Growth of Fresh Human TumorsJNCI Journal of the National Cancer Institute, 1992
- Inhibition of Human Immunodeficiency Virus Type I Reverse Transcriptase by Suramin-related CompoundsJournal of General Virology, 1987